| 08/06/2026 10:55 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/02/2026 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 07/31/2026 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 3:16 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/30/2026 3:05 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3/A | |
| 07/22/2026 7:37 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/25/2026 8:25 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/17/2026 3:30 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 3:30 PM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 8:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NRSNW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/09/2026 9:13 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/08/2026 8:05 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/28/2026 2:38 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/24/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/06/2026 8:20 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/03/2026 8:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/01/2026 3:25 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 04/01/2026 3:26 PM | Eisenberg Or (1721412) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/31/2026 3:16 PM | Mandil-Levin Revital (2125058) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 03/31/2026 8:29 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 7:49 AM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/30/2026 7:51 AM | Ben-Noon Alon (1901198) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/24/2026 9:11 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/18/2026 2:35 PM | Binder Hagit (2118272) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Leuchtenberger Mark (1303315) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:35 PM | Golan Roy (1999257) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | Claiborne Cary J (1370930) Reporting NeuroSense Therapeutics (1875091) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 03/18/2026 2:36 PM | NeuroSense Therapeutics (1875091) Issuer Tracik Ferenc (2120172) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 03/16/2026 11:27 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/11/2026 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/18/2026 8:21 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 8:30 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 01/29/2026 4:28 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 01/06/2026 4:27 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/22/2025 10:49 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/08/2025 7:00 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/04/2025 7:39 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/26/2025 3:15 PM | NeuroSense Therapeutics (1875091) Filer | Form 424B3 | |
| 11/25/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
ALERT: Drop these 5 stocks before the market opens tomorrow! (Ad) The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. See the 5 stocks to avoid |
| 11/21/2025 5:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/28/2025 3:26 PM | NeuroSense Therapeutics (1875091) Filer | Form F-3 Registration statement for securities of certain foreign private issuers | |
| 10/06/2025 8:06 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/25/2025 8:23 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 1:35 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 7:59 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/04/2025 8:01 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/02/2025 7:36 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/21/2025 3:56 PM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/20/2025 8:31 AM | NeuroSense Therapeutics (1875091) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |
| 08/18/2025 11:15 PM | NeuroSense Therapeutics (1875091) Filer | Form EFFECT | |